TQ-A3334 not checked

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · AL-034

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Chronic Hepatitis B
Main trialPhase 2
“This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.”In the company’s words, NCT06706310 on ClinicalTrials.gov
Other names
AL-034

Other drugs for Chronic Hepatitis B

All 33 drugs for Chronic Hepatitis B

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 7 Dec 2025 Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
Phase 1/2Terminated 25 Aug 2023 A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
Phase 1Completed 14 Nov 2018 A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
Phase 1Completed 24 Jun 2024 A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow TQ-A3334

Following is part of Solo: you see every change to TQ-A3334 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in